Building a genetic atlas of the human plasma proteome
The link between a genetic variant and its associated disease endpoint is often indirect. For this reason, genome-wide association studies (GWAS) alone have limited utility in clinical research. By identifying the abundance of particular proteins associated with GWAS variants, we can begin to fill in the gaps. Protein-genotype associations, also called pQTLs, can shed light on causal links between genetic variants and disease and highlight clinically important proteins. However, pQTL analyses have typically been restricted to small scale studies in particular cell lines, due to the technical difficulty of measuring the human proteome at scale. In this webinar, Dr. Benjamin Sun will discuss how he and his colleagues at the University of Cambridge used the SomaScan® Assay to develop a pQTL atlas of human plasma. In a study published in Nature in 2018, they quantified 3,622 plasma proteins in 3,301 healthy participants in order to identify 1,927 pQTLs. 88 of these pQTLs overlapped with disease susceptibility loci. Using Mendelian randomization analysis, Sun and colleagues further identified specific proteins that link GWAS variants to disease, highlighting potential therapeutic targets.
Benjamin Sun, PhD, MB, BChir
Royal Free Hospital, London, UK
Dr. Sun is a clinician and a scientist with a strong statistical and computational background. He got his PhD and clinical medicine degrees in a combined MB-PhD program in 2019 from the Department of Public Health and Primary Care at the University of Cambridge, where he was one of six students selected from a cohort of 300. His graduate work focused on big data research on genomic regulators of the human proteome. It was during this time that he authored the Nature publication describing the development of a “genomic atlas” of the human proteome using SomaScan data. Dr. Sun was an author on 13 additional publications during his time at Cambridge. Since completing his MB-PhD, Dr. Sun has been serving as a Foundation Doctor in Trauma and Orthopaedics, Renal Medicine, and Respiratory Medicine at the Royal Free Hospital in London.
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.